Drugs / ZEN003365
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02238522 | Oct 2014 → Jun 2016 | acute myeloid leukemia, lymphoid neoplasm | Zenith Epigenetics | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZEN003365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02238522 ↗ |
| Route | Oral | “ZEN003365 will be administered orally as a single agent” NCT02238522 ↗ |